Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharm... (t-graduate work in comparativeanatomy an...)

Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals

Date:6/23/2008

t-graduate work in comparative anatomy and physiology of the eye at the University of Waterloo in Canada, where he received a Master of Science degree. Dr. Levy has published widely in peer-reviewed journals and has presented nationally and internationally at scientific and educational symposia of Ophthalmology.

About Danube Pharmaceuticals, Inc.

Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit http://www.danubepharma.com.

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statements. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to success
'/>"/>

1

GOOD

Page: 1 2 3
Related biology technology :

1. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
2. MiMedx Announces Brian J. Splan as President
3. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
6. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
7. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
8. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
9. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
10. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services

Post Your Comments:

Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharm...(t-graduate work in comparativeanatomy an...)